We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

14 hedge funds and large institutions have $2.39M invested in ABVC BioPharma in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

192% more capital invested

Capital invested by funds: $817K → $2.39M (+$1.57M)

56% more funds holding

Funds holding: 9 → 14 (+5)

1.17% more ownership

Funds ownership: 2.16% → 3.34% (+1.2%)

Holders
14
Holders Change
+5
Holders Change %
+55.56%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
6
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$479K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$237K
3
Renaissance Technologies
Renaissance Technologies
New York
+$211K
4
State Street
State Street
Massachusetts
+$184K
5
BlackRock
BlackRock
New York
+$173K

Top Sellers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
-$85.5K
2
Northern Trust
Northern Trust
Illinois
-$37.9K
3
SS
SBI Securities
Japan
-$1.07K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$813K +$479K +155,917 +140%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$571K +$237K +77,313 +70%
Renaissance Technologies
3
Renaissance Technologies
New York
$336K +$211K +68,794 +165%
State Street
4
State Street
Massachusetts
$221K +$184K +59,900 +464%
BlackRock
5
BlackRock
New York
$172K +$173K +56,442 New
Northern Trust
6
Northern Trust
Illinois
$75.5K -$37.9K -12,323 -33%
XT
7
XTX Topco
Cayman Islands
$75.4K -$85.5K -27,824 -53%
Millennium Management
8
Millennium Management
New York
$59.6K +$60.2K +19,603 New
Citadel Advisors
9
Citadel Advisors
Florida
$47.6K +$48.1K +15,664 New
TRCT
10
Tower Research Capital (TRC)
New York
$6.55K +$5.53K +1,801 +509%
UBS Group
11
UBS Group
Switzerland
$5.62K +$5.68K +1,849 New
Simplex Trading
12
Simplex Trading
Illinois
$3K +$3.4K +1,108 New
Bank of America
13
Bank of America
North Carolina
$532 +$129 +42 +32%
Northwestern Mutual Wealth Management
14
Northwestern Mutual Wealth Management
Wisconsin
$456 +$461 +150 New
SS
15
SBI Securities
Japan
– -$1.07K -483 Closed

ABVC Hedge Fund Activity: Q3 2025 in Review

14 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q3 2025, worth a combined $2.39M — up 192% from $817K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ABVC positions and 1 closed out — a net gain of 5 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $479K. The largest seller was XTX Topco, cutting an estimated $85.5K.

  • 14 institutional investors held ABVC BioPharma (ABVC) as of Q3 2025, up from 9 in Q2 2025.
  • Funds reported $2.39M of ABVC BioPharma stock for Q3 2025, up 192% quarter-over-quarter.
  • 6 funds opened new ABVC BioPharma positions in Q3 2025 and 1 closed out, a net change of +5 holders.
  • The largest ABVC BioPharma buyer in Q3 2025 was Vanguard Group, an estimated $479K added.
  • The largest ABVC BioPharma seller in Q3 2025 was XTX Topco, an estimated $85.5K sold.

Based on aggregated 13F filings for Q3 2025.